Phase II study of azacitidine to restore responsiveness of prostate cancer to hormonal therapy

Clinical Genitourinary Cancer

Volumn 5, Issue 7, 2007, Pages 457-459

  Sonpavde, Guru ^a,e   Aparicio, Ana ^b   Guttierez, Israel ^c   Boehm, Kristi A ^a   Hutson, Thomas E ^a   Berry, William R ^a   Asmar, Lina ^a   Von Hoff, Daniel D ^d  

^a US Oncology Research

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c CELGENE CORPORATION   (United States)

^d TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^e Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

Author keywords

Androgen deprivation therapy; Myelodysplastic syndrome; Prostate specific antigen

Indexed keywords

ANTIANDROGEN; AZACITIDINE; DNA; GONADORELIN; GROWTH FACTOR; HEMOGLOBIN F; PROSTATE SPECIFIC ANTIGEN; SEROTONIN 3 ANTAGONIST;

ADD ON THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CANCER HORMONE THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CORRELATION ANALYSIS; DNA METHYLATION; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG RESPONSE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; PROSTATE CANCER;

EID: 38949164700     PISSN: 15587673     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2007.n.036     Document Type: Article

References (30)

1. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
2. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351:1513-20.
3. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349:2042-54.
4. Das PM, Singal R. DNA methylation and cancer. J Clin Oncol 2004; 22:4632-42.
5. Izbicka E, Davidson K, Lawrence RA, et al. 5,6-dihydro-5′ azacytidine (DHAC) affects estrogen sensitivity in estrogren-refractory human breast carcinoma cell lines. Anticancer Res 1999; 19:1293-8.
6. Izbicka E, MacDonald JR, Davidson K, et al. 5,6-dihydro-5′ azacytidine (DHAC) restores androgen responsiveness in androgen-insensitive prostate cancer cells. Anticancer Res 1999; 19:1285-92.
7. Zhao H, Shiina H, Greene KL, et al. CpG methylation at promoter site -140 inactivates TGFbeta2 receptor gene in prostate cancer. Cancer 2005; 104:44-52.
8. Wang LG, Ossowski L, Ferrari AC. Androgen receptor level controlled by a suppressor complex lost in an androgen-independent prostate cancer cell line. Oncogene 2004; 23:5175-84.
9. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005; 23:8253-61.
10. Edwards J, Bartlett J. The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: modifications to the androgen receptor. BJU Int 2005; 95:1320-6.
11. Nelson WG, De Marzo DM, Isaacs WB. Prostate cancer. N Engl J Med 2003; 349:366-81.
12. Kitagawa Y, Kyo S, Takakura M, et al. Demethylating reagent 5-azacytidine inhibits telomerase activity in human prostate cancer cells through transcriptional repression of hTERT. Clin Cancer Res 2000; 6:2868-75.
13. Thibault A, Figg WD, Bergan RC, et al. A phase II study of 5-aza-2′deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer. Tumori 1998; 84:87-9.
14. Methylation inhibitor therapy in the treatment of myelodysplastic syndrome. Nat Clin Pract Oncol 2005; 2(suppl 1):S12-23.
15. Daskalakis M, Nguyen TT, Nguyen C, et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2′-deoxycytidine (decitabine) treatment. Blood 2002; 100:2957-64.
16. Pfeifer GP, Steigerwald SD, Hansen RS, et al. Polymerase chain reaction-aided genomic sequencing of an X chromosome-linked CpG island: methylation patterns suggest clonal inheritance, CpG site autonomy, and an explanation of activity state stability. Proc Natl Acad Sci U S A 1990; 87:8252-6.
17. Silverman LR, Demakos LP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol 2002; 20:2429-40.
18. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group [published correction appears in J Clin Oncol 2000; 18:2644]. J Clin Oncol 1999; 17:3461-7.
19. D'Amico AV, Moul J, Carroll PR, et al. Surrogate end point for prostate cancer specific mortality in patients with nonmetastatic hormone refractory prostate cancer. J Urol 2005; 173:1572-6.
20. Smith MR, Kabbinavar F, Saad F, et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 2005; 23:2918-25.
21. D'Amico AV, Halabi S, Vogelzang NJ, et al. A reduction in the rate of PSA rise following chemotherapy in patients with metastatic hormone refractory prostate cancer (HRPC) predicts survival: results of a pooled analysis of CALGB HRPC trials. Proc Am Soc Clin Oncol 2004; 22(14 suppl):382 (Abstract 4506).
22. Small EJ, Schellhammer PF, Higano CS, et al. Results of a placebo-controlled phase III trial of immunotherapy with APC8015 for patients with hormone refractory prostate cancer. J Clin Oncol 2005; 23(16 suppl): 378s (Abstract 4500).
23. Vogelzang NJ, Nelson JB, Schulman CC, et al. Meta-analysis of clinical trials of atrasenran 10 mg in metastatic hormone-refractory prostate cancer. J Clin Oncol 2005; 23(16 suppl):379s (Abstract 4563).
24. Stewart AJ, Scher HI, Chen MH, et al. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol 2005; 23:6556-60.
25. Charache S, Dover G, Smith K, et al. Treatment of sickle cell anemia with 5-azacytidine results in increased fetal hemoglobin production and is associated with nonrandom hypomethylation of DNA around the gamma-delta-beta- globin gene complex. Proc Natl Acad Sci U S A 1983; 80:4842-6.
26. Jeronimo C, Usadel H, Henrique R, et al. Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. Urology 2002; 60:1131-5.
27. Yoder JA, Walsh CP, Bestor TH. Cytosine methylation and the ecology of intragenomic parasites. Trends Genet 1997; 13:335-40.
28. Yang AS, Estécio MR, Doshi K, et al. A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res 2004; 32:e38.
29. Issa JP. DNA methylation in the treatment of hematologic malignancies. Clin Adv Hematol Oncol 2005; 3:684-6.
30. Hoque MO, Topaloglu O, Begum S, et al. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguishes prostate cancer patients from control subjects. J Clin Oncol 2005; 23:6569-75.